Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
908 Devices announced the appointment of Kevin Hrusovsky as Chairman of its Board of Directors. Hrusovsky, a veteran in biotechnology and CEO of Quanterix (NASDAQ: QTRX), brings extensive experience in commercializing disruptive healthcare technologies. His leadership is expected to bolster 908 Devices’ mission of democratizing mass spectrometry for critical applications in life sciences, bioprocessing, and forensics. Hrusovsky's commitment to transforming healthcare through advanced analytical tools positions the company well at a pivotal moment for next-gen proteomics.
Quanterix Corporation (NASDAQ: QTRX) announced it will release its third-quarter 2020 financial results on November 5, 2020, after the market closes. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the call by dialing the provided numbers or through a live webcast available on Quanterix's website for a year post-call. The company specializes in advanced biomarker analysis to enhance precision health, focusing on various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present at the Precision Medicine Leaders Summit's Precision Oncology Conference today at 3:15 p.m. EDT. His keynote, titled “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will highlight advances in multiplex assays that enable the identification of multiple oncology biomarkers simultaneously. This technology allows for early cancer detection and enhances the efficacy of immuno-oncology treatments. For more details, visit www.quanterix.com.
Quanterix Corporation (NASDAQ: QTRX) announced a Phase 2 contract with the National Institutes of Health, valued at $18.2 million, to advance a novel SARS-CoV-2 antigen test utilizing their Simoa technology. This funding supports clinical validation and aims for emergency use authorization submissions with the FDA. The contract also facilitates expanded manufacturing capacities at Quanterix's Billerica, Massachusetts facility. Initial feasibility of the test was previously supported by a Phase 1 award. The contract period extends through September 2021.
Quanterix Corporation (NASDAQ: QTRX) has entered a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), granting Abbott access to Quanterix's bead-based technology patents for in vitro diagnostic (IVD) applications. This agreement includes an initial license fee, milestone fees contingent on Abbott's future development achievements, and royalties on sales of licensed products. Quanterix aims to advance precision health through its digital health solution, Simoa, improving disease detection and treatment methods.